More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings the PREDIX HER2 trial

Human epidermal growth factor receptor-2 (HER 2) positive breast cancers represent a highly aggressive cancer subtype and are associated witha worse prognosis. They tend to be more with lower survival rates but better prognosis than the triple-negative subtype.

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity. Overexpression of HER2 usually causes malignant transformation of cells and is responsible for the breast cancer. In this work, the virtual screening, molecular docking, quantum mechanics and molecular dynamics methods were employed to study protein–ligand ...